Artificial intelligence (AI) is increasingly being explored as a tool in glioma care, but experts emphasize both its potential and its limitations.
Dr. Katherine Peters of Duke University’s Preston Robert Tisch Brain Tumor Center noted, “We need as many tools as we can get, and if AI is one of them, I’m all for it. But with any AI instrument, the quality of the input is critical—without strong data, the output can be flawed. Sometimes the answers are wrong, so careful input is essential.” She also raised questions about how molecular and genetic information can be effectively integrated into AI systems for clinical use.
Dr. Kathryn Nevel, a neurologist and neuro-oncologist at Indiana University School of Medicine, underscored the importance of human oversight. “I think the human connection is so important. You’ll always need the knowledge to interpret and judge the AI,” she said, highlighting that technology should complement—not replace—the clinician’s expertise.
